Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Raw Materials (2020 - 2025)

Maxcyte (MXCT) has disclosed Raw Materials for 6 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • Quarterly Raw Materials fell 18.08% to $3.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.9 million through Dec 2025, down 18.08% year-over-year, with the annual reading at $3.9 million for FY2025, 18.08% down from the prior year.
  • Raw Materials for Q4 2025 was $3.9 million at Maxcyte, roughly flat from $3.9 million in the prior quarter.
  • The five-year high for Raw Materials was $6.0 million in Q1 2023, with the low at $1.6 million in Q3 2021.
  • Average Raw Materials over 5 years is $4.5 million, with a median of $4.7 million recorded in 2024.
  • The sharpest move saw Raw Materials soared 224.18% in 2022, then plummeted 30.53% in 2025.
  • Over 5 years, Raw Materials stood at $2.7 million in 2021, then skyrocketed by 110.54% to $5.7 million in 2022, then rose by 0.76% to $5.7 million in 2023, then fell by 17.16% to $4.7 million in 2024, then dropped by 18.08% to $3.9 million in 2025.
  • According to Business Quant data, Raw Materials over the past three periods came in at $3.9 million, $3.9 million, and $4.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.